A rationale to target the SWI/SNF complex for cancer therapy

Hohmann, A. F., Vakoc, C. R. (June 2014) A rationale to target the SWI/SNF complex for cancer therapy. Trends in Genetics, 30 (8). pp. 356-363. ISSN 01689525

URL: http://www.ncbi.nlm.nih.gov/pubmed/24578380
DOI: 10.1016/j.tig.2014.05.001

Abstract

SWI/SNF is a multisubunit chromatin-remodeling complex that performs fundamental roles in gene regulation, cell lineage specification, and organismal development. Mutations that inactivate SWI/SNF subunits are found in nearly 20% of human cancers, which indicates that the proper functioning of this complex is necessary to prevent tumor formation in diverse tissues. Recent studies show that SWI/SNF-mutant cancers depend on residual SWI/SNF complexes for their aberrant growth, thus revealing synthetic lethal interactions that could be exploited for therapeutic purposes. Other studies reveal that certain acute leukemias and small cell lung cancers, which lack SWI/SNF mutations, can be vulnerable to inhibition of the SWI/SNF ATPase subunit BRG1, whereas several normal and malignant cell types do not show this sensitivity. Here, we review the emerging evidence that implicates SWI/SNF as a tumor-dependency and candidate drug target in human cancer. © 2014 Elsevier Ltd. All rights reserved.

Item Type: Paper
Uncontrolled Keywords: cancer therapy SWI/SNF synthetic lethality
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Vakoc lab
Watson School > Publications
Depositing User: Matt Covey
Date: 20 June 2014
Date Deposited: 13 Jun 2014 16:06
Last Modified: 17 Apr 2015 14:28
PMCID: PMC4024079
Related URLs:
URI: http://repository.cshl.edu/id/eprint/30300

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving